You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CLINICAL TRIALS PROFILE FOR BIMATOPROST


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for BIMATOPROST

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01325337 ↗ Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed Allergan Phase 2 2011-06-01 This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC NCT01325350 ↗ Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss Completed Allergan Phase 2 2011-06-01 This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.
New Formulation NCT01426113 ↗ A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma Terminated Allergan Phase 3 2011-09-01 The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for BIMATOPROST

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00187577 ↗ Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Completed University of California, San Francisco N/A 2005-06-01 This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day.
NCT00273455 ↗ Lumigan Versus Cosopt Completed Pharmaceutical Research Network Phase 4 2006-01-01 To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy
NCT00300443 ↗ Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension Completed Allergan Phase 2/Phase 3 2005-12-01 The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension
NCT00332059 ↗ Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension Completed Allergan Phase 3 2003-05-01 The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
NCT00332072 ↗ Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension Completed Allergan Phase 3 2001-08-01 The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in the treatment of glaucoma or ocular hypertension
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BIMATOPROST

Condition Name

Condition Name for BIMATOPROST
Intervention Trials
Ocular Hypertension 70
Glaucoma 41
Glaucoma, Open-Angle 21
Open-Angle Glaucoma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for BIMATOPROST
Intervention Trials
Glaucoma 76
Ocular Hypertension 73
Hypertension 58
Glaucoma, Open-Angle 44
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BIMATOPROST

Trials by Country

Trials by Country for BIMATOPROST
Location Trials
United States 282
Germany 24
Italy 23
Canada 22
United Kingdom 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for BIMATOPROST
Location Trials
California 38
Texas 19
Georgia 14
Pennsylvania 14
North Carolina 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BIMATOPROST

Clinical Trial Phase

Clinical Trial Phase for BIMATOPROST
Clinical Trial Phase Trials
Phase 4 48
Phase 3 30
Phase 2/Phase 3 1
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for BIMATOPROST
Clinical Trial Phase Trials
Completed 105
Withdrawn 4
Not yet recruiting 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BIMATOPROST

Sponsor Name

Sponsor Name for BIMATOPROST
Sponsor Trials
Allergan 75
Alcon Research 7
ForSight Vision5, Inc. 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for BIMATOPROST
Sponsor Trials
Industry 102
Other 40
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.